Users of Zepbound or Mounjaro Had Lower Blood Pressure in Studynews2024-02-05T16:10:45+00:00February 5th, 2024|The New York Times|
6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptionsnews2024-02-02T20:20:57+00:00February 2nd, 2024|The New York Times|
Eli Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealthnews2024-01-05T21:20:53+00:00January 5th, 2024|The New York Times|
Zepbound, el nuevo medicamento aprobado por la FDA para perder pesonews2023-11-13T10:01:53+00:00November 13th, 2023|The New York Times|
F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovynews2023-11-09T01:02:09+00:00November 9th, 2023|The New York Times|
FDA Approves Zepbound, A Drug Like Ozempic, for Weight Loss. Here’s What to Know.news2023-11-08T18:34:20+00:00November 8th, 2023|The New York Times|
Los medicamentos cotra la obesidad tienen sobreprecio, pero esto puede cambiarnews2023-10-26T09:02:55+00:00October 26th, 2023|The New York Times|
How Much Do Ozempic and Wegovy Cost? Not What You Think.news2023-10-22T07:00:20+00:00October 22nd, 2023|The New York Times|
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Diseasenews2023-05-03T21:57:13+00:00May 3rd, 2023|The New York Times|
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cutsnews2023-03-24T15:25:37+00:00March 24th, 2023|The New York Times|
